Brief: NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Neurosense Therapeutics

05/12/2023 13:29

Dec 5 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE'S PHASE 2B ALS TRIAL ACHIEVES PRIMARY SAFETY
AND
TOLERABILITY & SECONDARY CLINICAL EFFICACY ENDPOINTS
    * NEUROSENSE THERAPEUTICS LTD - PRIMARY BIOMARKER ENDPOINTS
AND
EXPLORATORY BIOMARKERS FROM THIS TRIAL, EXPECTED IN H1 2024
    * NEUROSENSE THERAPEUTICS LTD - NEUROFILAMENT BIOMARKER
RESULTS
FROM BIOGEN COLLABORATION EXPECTED IN JANUARY 2024

Source text for Eikon:  ID:nPn7CcMPFa 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))